Latest news with #CLIA-certified
Business Wire
2 days ago
- Business
- Business Wire
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code is 859170. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.
Yahoo
24-06-2025
- Business
- Yahoo
Circulogene Launches LungLifeAI® Nationally Through Primary Care Channel
PENSACOLA, Fla., June 24, 2025 /PRNewswire/ -- Circulogene, a leading provider of precision diagnostics for lung cancer, has announced the national commercial launch of LungLifeAI®, now available across its expanding base of primary care clients. LungLifeAI® is an AI-powered blood test that supports early lung cancer detection by helping physicians assess malignancy risk in indeterminate pulmonary nodules (IPNs) found on CT scans. With an 80% positive predictive value, the test provides physicians with greater confidence in determining whether a biopsy or further evaluation is warranted. "This marks a major step forward in our mission to transform early lung cancer detection," said Mike Mullen, CEO of Circulogene. "Primary care physicians are often the first to identify risk. LungLifeAI® gives them a powerful, accessible tool to act quickly—and potentially save lives." This launch highlights the industry's growing focus on earlier intervention. For lung cancer—where screening pathways remain limited—LungLifeAI® offers a valuable option to close the gap in front-line clinical decision-making. The test requires only a standard blood draw and delivers results quickly, enhancing access for physicians and patients alike. "This isn't just innovation in diagnostics—it's innovation in access," added Mullen. LungLifeAI® uses proprietary AI algorithms to analyze circulating genetically abnormal cells (CGACs) in the blood, helping identify early cancer risk even when nodules appear small or ambiguous. The result is faster, more informed decisions that may reduce diagnostic delays and improve patient outcomes. About Circulogene Circulogene is a Birmingham-based precision medicine company advancing early-stage cancer detection through innovative liquid biopsy solutions. The company operates a CAP- and CLIA-certified lab and introduced the first blood-based PD-L1 test to market. Learn more at View original content to download multimedia: SOURCE Circuologene Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
24-06-2025
- Business
- Yahoo
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
FORT MYERS, Fla., June 24, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue and pipeline investment. "We are thrilled to welcome Marjorie to the NeoGenomics Board," said Lynn Tetrault, Chair of the Board of NeoGenomics. "Dr. Green's deep expertise in clinical oncology and pipeline development, combined with her experience in business development, will be invaluable as we continue to accelerate innovation into the precision oncology market." Prior to joining Merck, Dr. Green served as Senior Vice President and Head of Late-Stage Development at Seagen. Prior to that, Dr. Green was Vice President of Product Development and Global Head of the Breast and Gynecologic Cancer Franchise at Genentech. She began her career as a Medical Oncologist and Associate Professor at MD Anderson Cancer Center where she later became the Medical Director of the Nellie B. Connally Breast Center. Dr. Green earned her BA in History from the University of Notre Dame and her MD from the University of Texas Medical Branch. She completed her residency in internal medicine at the University of Virginia School of Medicine and her medical oncology fellowship at the University of Texas MD Anderson Cancer Center. "I am honored to join NeoGenomics' Board at such an exciting time in the company's journey," said Dr. Marjorie Green. "Neo's unique oncology diagnostics offerings are well positioned for growth, and I look forward to contributing to the company's mission of improving patient care." About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward-Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project," "guidance," "plan," "potential" and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on Contacts Investor Contact Kendra Sweeneyir@ Media Contact Andrea Sampsonasampson@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
24-06-2025
- Business
- Business Wire
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue and pipeline investment. 'We are thrilled to welcome Marjorie to the NeoGenomics Board,' said Lynn Tetrault, Chair of the Board of NeoGenomics. 'Dr. Green's deep expertise in clinical oncology and pipeline development, combined with her experience in business development, will be invaluable as we continue to accelerate innovation into the precision oncology market.' Prior to joining Merck, Dr. Green served as Senior Vice President and Head of Late-Stage Development at Seagen. Prior to that, Dr. Green was Vice President of Product Development and Global Head of the Breast and Gynecologic Cancer Franchise at Genentech. She began her career as a Medical Oncologist and Associate Professor at MD Anderson Cancer Center where she later became the Medical Director of the Nellie B. Connally Breast Center. Dr. Green earned her BA in History from the University of Notre Dame and her MD from the University of Texas Medical Branch. She completed her residency in internal medicine at the University of Virginia School of Medicine and her medical oncology fellowship at the University of Texas MD Anderson Cancer Center. 'I am honored to join NeoGenomics' Board at such an exciting time in the company's journey,' said Dr. Marjorie Green. 'Neo's unique oncology diagnostics offerings are well positioned for growth, and I look forward to contributing to the company's mission of improving patient care.' About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward-Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as 'anticipate,' 'expect,' 'plan,' 'could,' 'would,' 'may,' 'will,' 'believe,' 'estimate,' 'forecast,' 'goal,' 'project,' 'guidance,' 'plan,' 'potential' and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Yahoo
18-06-2025
- Business
- Yahoo
BostonGene to Present AI-Powered Solutions Advancing Patient-Centric Drug Development at The Festival of Genomics & Biodata Boston 2025
BostonGene's VP of R&D Mike Goldberg PhD to Lead Session on Transforming Drug Development with AI and Precision Analytics WALTHAM, Mass., June 18, 2025--(BUSINESS WIRE)--BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced its participation in The Festival of Genomics & Biodata Boston, taking place June 24 - 25 at the Boston Convention & Exhibition Center in Boston, MA. The Festival of Genomics & Biodata Boston is the premier life sciences event in the U.S., bringing together thousands of global genomics and biodata professionals for two days of cutting-edge research, technology showcases and networking. The event spotlights the latest advances in genomic science and their real-world applications in healthcare and beyond. Mike Goldberg, PhD, BostonGene's Vice President of R&D, will host a session titled "Redefining Precision Oncology with an End-to-End AI Platform for Drug Development." The session will focus on how BostonGene's AI-driven technologies are accelerating innovation across the drug development process and enabling more personalized, data-driven approaches to cancer care. Session details: Date & time: Tuesday, June 24 | 4:40 PM – 5:10 PM Location: AI in Discovery Stage To schedule a meeting during the event, please contact Hannah Oman at events@ For more details about the event, visit The Festival of Genomics & Biodata website. About BostonGene Corporation BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit View source version on Contacts Media Contact: BostonGene Erin Keleher+ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
